Design of recombinant antibody microarrays for global proteome analysis
(2006)- Abstract
- Antibody-based microarrays are among the new, rapidly emerging technologies within the field of proteomics that has the potential to evolve into a key proteomic research tool, providing novel means to perform early diagnostics, identify biomarkers and gain insights into disease biology.
The aim of this thesis, based on five original papers, was to develop antibody microarrays based on human recombinant scFv antibody fragments for large-scale comprehensive proteome analysis. In order to accomplish that, several of the key technological antibody microarray parameters critical for complex proteome analysis were carefully addressed and optimized (paper I-IV). By successfully optimizing each of the features, a... (More) - Antibody-based microarrays are among the new, rapidly emerging technologies within the field of proteomics that has the potential to evolve into a key proteomic research tool, providing novel means to perform early diagnostics, identify biomarkers and gain insights into disease biology.
The aim of this thesis, based on five original papers, was to develop antibody microarrays based on human recombinant scFv antibody fragments for large-scale comprehensive proteome analysis. In order to accomplish that, several of the key technological antibody microarray parameters critical for complex proteome analysis were carefully addressed and optimized (paper I-IV). By successfully optimizing each of the features, a state-of-the-art recombinant antibody microarray technology platform was successfully designed. The recombinant antibody microarrays could readily be used to perform highly sensitive and multiplexed protein expression analysis of complex samples, such as human plasma. In the final study (paper V), we applied the optimized microarrays to analyze pancreatic cancer serum samples and compared the protein expression signature to healthy controls. The results showed that a pancreatic cancer associated protein signature could be identified that could discriminate between cancer patients and healthy controls with a 100 % specificity and sensitivity. In addition, we also identified a potential predictor signature, which could be used to identify two cohorts of patients based on the overall survival. These novel findings demonstrated the tremendous potential of antibody microarrays in cancer research and clinical applications. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/547708
- author
- Ingvarsson, Johan LU
- supervisor
- opponent
-
- Prof. Cahill, Dolores, National Centre for Human Proteomics, Dublin, Ireland
- organization
- publishing date
- 2006
- type
- Thesis
- publication status
- published
- subject
- keywords
- Bioteknik, oncoproteomics, Recombinant antibody microarray, scFv, Biotechnology, plasma proteome analysis
- pages
- 140 pages
- publisher
- Department of Immunotechnology, Lund University
- defense location
- Lundmarksalen, Astronomiska Institutionen, Sölvegatan 27, Lund
- defense date
- 2006-12-15 13:15:00
- ISBN
- 978-91-628-7011-9
- language
- English
- LU publication?
- yes
- id
- dd52125f-f85a-4532-8375-b11e5aff84a8 (old id 547708)
- date added to LUP
- 2016-04-04 10:13:39
- date last changed
- 2018-11-21 20:57:31
@phdthesis{dd52125f-f85a-4532-8375-b11e5aff84a8,
abstract = {{Antibody-based microarrays are among the new, rapidly emerging technologies within the field of proteomics that has the potential to evolve into a key proteomic research tool, providing novel means to perform early diagnostics, identify biomarkers and gain insights into disease biology.<br/><br>
<br/><br>
The aim of this thesis, based on five original papers, was to develop antibody microarrays based on human recombinant scFv antibody fragments for large-scale comprehensive proteome analysis. In order to accomplish that, several of the key technological antibody microarray parameters critical for complex proteome analysis were carefully addressed and optimized (paper I-IV). By successfully optimizing each of the features, a state-of-the-art recombinant antibody microarray technology platform was successfully designed. The recombinant antibody microarrays could readily be used to perform highly sensitive and multiplexed protein expression analysis of complex samples, such as human plasma. In the final study (paper V), we applied the optimized microarrays to analyze pancreatic cancer serum samples and compared the protein expression signature to healthy controls. The results showed that a pancreatic cancer associated protein signature could be identified that could discriminate between cancer patients and healthy controls with a 100 % specificity and sensitivity. In addition, we also identified a potential predictor signature, which could be used to identify two cohorts of patients based on the overall survival. These novel findings demonstrated the tremendous potential of antibody microarrays in cancer research and clinical applications.}},
author = {{Ingvarsson, Johan}},
isbn = {{978-91-628-7011-9}},
keywords = {{Bioteknik; oncoproteomics; Recombinant antibody microarray; scFv; Biotechnology; plasma proteome analysis}},
language = {{eng}},
publisher = {{Department of Immunotechnology, Lund University}},
school = {{Lund University}},
title = {{Design of recombinant antibody microarrays for global proteome analysis}},
year = {{2006}},
}